Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome

Apert syndrome (AS) is characterized by craniosynostosis (premature fusion of cranial sutures) and severe syndactyly of the hands and feet. Two activating mutations, Ser-252 → Trp and Pro-253 → Arg, in fibroblast growth factor receptor 2 (FGFR2) account for nearly all known cases of AS. To elucidate the mechanism by which these substitutions cause AS, we determined the crystal structures of these two FGFR2 mutants in complex with fibroblast growth factor 2 (FGF2) . These structures demonstrate that both mutations introduce additional interactions between FGFR2 and FGF2, thereby augmenting FGFR2–FGF2 affinity. Moreover, based on these structures and sequence alignment of the FGF family, we propose that the Pro-253 → Arg mutation will indiscriminately increase the affinity of FGFR2 toward any FGF. In contrast, the Ser-252 → Trp mutation will selectively enhance the affinity of FGFR2 toward a limited subset of FGFs. These predictions are consistent with previous biochemical data describing the effects of AS mutations on FGF binding. Alterations in FGFR2 ligand affinity and specificity may allow inappropriate autocrine or paracrine activation of FGFR2. Furthermore, the distinct gain-of-function interactions observed in each crystal structure provide a model to explain the phenotypic variability among AS patients.

[1]  G. Waksman,et al.  Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[3]  E. Zackai,et al.  Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes , 1996, Nature Genetics.

[4]  R. Friesel,et al.  Constitutive Activation of Fibroblast Growth Factor Receptor-2 by a Point Mutation Associated with Crouzon Syndrome (*) , 1995, The Journal of Biological Chemistry.

[5]  J. Richman,et al.  Effect of fibroblast growth factors on outgrowth of facial mesenchyme. , 1997, Developmental biology.

[6]  W. Reardon,et al.  Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome , 1995, Nature Genetics.

[7]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[8]  J. Hurst,et al.  Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. , 1996, American journal of human genetics.

[9]  R. Gorlin.  Fibroblast growth factors, their receptors and receptor disorders. , 1997, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[10]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[11]  V. Sasisekharan,et al.  Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Martine Le Merrer,et al.  Clinical variability in patients with Apert's syndrome. , 1999 .

[13]  E. Zackai,et al.  De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome. , 1999, American journal of human genetics.

[14]  J. Gabriel,et al.  Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. , 1999, Biochemistry.

[15]  J. Schlessinger,et al.  Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. , 2000, Molecular cell.

[16]  David F. Burke,et al.  Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin , 2000, Nature.

[17]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[18]  Joseph Schlessinger,et al.  Crystal Structures of Two FGF-FGFR Complexes Reveal the Determinants of Ligand-Receptor Specificity , 2000, Cell.

[19]  W. Hendrickson,et al.  Structural interactions of fibroblast growth factor receptor with its ligands. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[21]  D. Rees,et al.  Diversity does make a difference: fibroblast growth factor-heparin interactions. , 1998, Current opinion in structural biology.

[22]  E. Jabs,et al.  The pleiotropic effects of fibroblast growth factor receptors in mammalian development. , 2000, Cell structure and function.

[23]  R. Friesel,et al.  Ligand-independent Activation of Fibroblast Growth Factor Receptors by Point Mutations in the Extracellular, Transmembrane, and Kinase Domains* , 1996, The Journal of Biological Chemistry.

[24]  A. N. Meyer,et al.  Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Heath,et al.  Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. , 1998, Human molecular genetics.

[26]  M. Muenke,et al.  Craniosynostosis syndromes: from genes to premature fusion of skull bones. , 1999, Molecular genetics and metabolism.

[27]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[28]  W. Reardon,et al.  A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome , 1994, Nature Genetics.

[29]  S. Hubbard,et al.  Structural Basis for FGF Receptor Dimerization and Activation , 1999, Cell.

[30]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[31]  C. Basilico,et al.  Signaling by Fibroblast Growth Factors (Fgf) and Fibroblast Growth Factor Receptor 2 (Fgfr2)–Activating Mutations Blocks Mineralization and Induces Apoptosis in Osteoblasts , 2000, The Journal of cell biology.

[32]  D. Johnson,et al.  Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.